Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial and cellular components susceptible to reactive oxygen species (ROS) encompass a broad range of biomolecules, including mitochondrial DNA (mtDNA), polyunsaturated fatty acids in lipid membranes, and specific redox-sensitive proteins (Murphy, 2009, Biochem J). ROS are primarily generated as byproducts of the mitochondrial electron transport chain, and when their production exceeds the capacity of the cell's antioxidant defenses, oxidative damage occurs (Shokolenko et al., 2009, Antioxid Redox Signal). This damage can lead to mitochondrial dysfunction, impaired ATP production, and the induction of apoptotic pathways through the release of cytochrome c (Ayala et al., 2014, Oxid Med Cell Longev). Oxidative stress is a central feature in the pathogenesis of various conditions, including neurodegenerative diseases like Parkinson's and Alzheimer's, cardiovascular disorders, and the biological aging process (Sies et al., 2017, Nat Rev Mol Cell Biol). Therapeutic interventions often utilize mitochondria-targeted antioxidants, such as MitoQ or Idebenone, to scavenge ROS directly or protect specific mitochondrial components from oxidative degradation (Smith & Murphy, 2010, Free Radic Biol Med). Because this term refers to a collective group of molecules rather than a single protein or receptor, it is categorized as a descriptive pathway target rather than a specific molecular entity.
Scavenging of reactive oxygen species, inhibition of ROS-generating enzymes (such as NADPH oxidase), or induction of endogenous antioxidant pathways (e.g., Nrf2 activation) to protect cellular structures from oxidative damage.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial and cellular components susceptible to ROS.